Department of Respiratory & Critical Care Medicine, Targeted Tracer Research & development laboratory, West China Hospital, Sichuan University, Chengdu, 610041, China.
Cancer Center, West China Hospital, Sichuan University & Collaborative Innovation Center of Biotherapy, Chengdu, 610041, China.
Future Med Chem. 2022 Jun;14(11):785-794. doi: 10.4155/fmc-2021-0124. Epub 2022 May 4.
Tubulin protein is a promising target for antitumor drugs. Some tubulin inhibitors targeting the colchicine binding site are not substrates of the multidrug-resistance efflux pump, which can overcome the mechanism of drug resistance mediated by P-glycoprotein. SSE15206 is a colchicine binding site inhibitor with antiproliferative activity against different drug-resistant cell lines. Unfortunately, the lack of detailed interaction information about SSE15206 in complex with tubulin impeded the development of potent drugs that possess similar scaffolds. Herein, the authors report the crystal structure of the tubulin-SSE15206 complex at a resolution of 2.8 Å. The complex structure reveals the intermolecular interactions between SSE15206 and tubulin, providing a rationale for the development of pyrazolinethioamides as tubulin polymerization inhibitors and to overcome multidrug resistance.
微管蛋白是抗肿瘤药物的一个有前途的靶点。一些靶向秋水仙素结合位点的微管蛋白抑制剂不是多药耐药外排泵的底物,这可以克服 P 糖蛋白介导的耐药机制。SSE15206 是一种秋水仙素结合位点抑制剂,对不同耐药细胞系具有抗增殖活性。不幸的是,由于缺乏 SSE15206 与微管蛋白复合物的详细相互作用信息,阻碍了具有类似支架的有效药物的开发。本文作者报道了 SSE15206 与微管蛋白复合物的晶体结构,分辨率为 2.8Å。该复合物结构揭示了 SSE15206 与微管蛋白之间的分子间相互作用,为将吡唑啉硫代酰胺类化合物作为微管蛋白聚合抑制剂开发并克服多药耐药性提供了依据。